It is currently Sun May 29, 2016 4:15 pm

News News of General Discussion

Site map of General Discussion » Forum : General Discussion

If it's on your mind and it has to do with multiple sclerosis in any way, post it here.

DMF ‘significantly reduces disability progression’

Delayed-release dimethyl fumarate (DMF) has been associated with significant reductions in confirmed disability progression (CDP) in patients newly diagnosed with relapsing-remitting multiple sclerosis (RRMS), compared with placebo, presented J. Theodore Phillips, MD, PhD, FAAN, Baylor Institute for Immunology Research, Dallas, TX, at the 68th American Academy of Neurology meeting in Vancouver, Canada...Read more - http://www.ms-uk.org/MSnews
Read more : DMF ‘significantly reduces disability progression’ | Views : 447 | Replies : 0


Daclizumab HYP improves cognition - report

Patients with relapsing-remitting multiple sclerosis (MS) treated with daclizumab high-yield process (HYP) had improved cognitive outcomes at 96 weeks compared with beta interferon, a study presented at the 68th American Academy of Neurology meeting has found...Read more - http://www.ms-uk.org/MSnews
Read more : Daclizumab HYP improves cognition - report | Views : 344 | Replies : 0


Parkinson's blood test developed

http://www.skynews.com.au/news/national/2016/04/20/parkinson-s-blood-test-developed.html
Although this is not MS specific, what did peak my interest is that it is based on
The researchers measured the activity of mitochondria, 'the small energy powerhouses in cells', in 29 people with Parkinson's and nine without the disease.

'We had expected there would be a reduction in the activity of the Parkinson's cells, but we actually found the reverse,' Prof Fisher said.

'They were four times more active than in the healthy ...
Read more : Parkinson's blood test developed | Views : 323 | Replies : 0


NEDA-3, NEDA-4 and my complain

Some years ago, only the clinical relapses were a valid marker of MS evolution. Today MRI has changed the picture and the concept of NEDA (No Evidence of Disease Activity) has appeared.

First it was NEDA-3 (no MRI activity, no relapses and no clinical progression). Currently it is being replaced by NEDA-4 (same three conditions as before plus no brain shrinkage, http://www.novartis.com.ph/newsroom/201 ... 8_001.html)

And now my complain. The ...
Read more : NEDA-3, NEDA-4 and my complain | Views : 351 | Replies : 2


Interferon ‘does not increase antidepressant use....

Interferon ‘does not increase antidepressant use in MS population’

No correlation between interferon treatment and antidepressant use has been observed in the multiple sclerosis (MS) population, a large-scale study presented at the 68th AAN Annual Meeting reported...Read More - http://www.ms-uk.org/MSnews
Read more : Interferon ‘does not increase antidepressant use.... | Views : 323 | Replies : 0


Multiple sclerosis relapses ‘common’ during 20-year period

Regardless of whether the disease is in the progressive phase or not, patients with multiple sclerosis (MS) seem likely to experience relapses for the first time or relapse continuation between the ages of 27 and 47 years according to a new study...Read More - http://www.ms-uk.org/MSnews
Read more : Multiple sclerosis relapses ‘common’ during 20-year period | Views : 448 | Replies : 1


The MS-UK Virtual Insight Panel

Find out how you could be a VIP and join our Virtual Insight Panel http://www.ms-uk.org/vip

Image
Read more : The MS-UK Virtual Insight Panel | Views : 295 | Replies : 0


Data shows Cladribine benefits persist in RRMS patients

The effects of Cladribine for relapsing-remitting multiple sclerosis (RRMS) patients have been demonstrated to last for up to four years after treatment has started, according to the findings of a study presented at the 68th American Academy of Neurology Annual Meeting...Read More - http://www.ms-uk.org/MSnews
Read more : Data shows Cladribine benefits persist in RRMS patients | Views : 325 | Replies : 0


Patients ‘tolerate arbaclofen extended-release tabs’

Arbaclofen extended-release tablets (AERT) have proved to have greater tolerability, and similar efficacy and safety, to baclofen in patients with multiple sclerosis (MS), according to randomised trial results reported at the 68th American Academy of Neurology annual Meeting...Read More - http://www.ms-uk.org/MSnews
Read more : Patients ‘tolerate arbaclofen extended-release tabs’ | Views : 304 | Replies : 0


AAN Conference Interview - Personalised medicine in MS

Hi everyone,

As part of our coverage of the current American Academy of Neurology conference happening in Vancouver, we are conducting interviews with researchers that are in attendance. Today, we have published our interview with Dr Tomas Kalincik. Dr Kalincik is a researcher from the Melbourne Brain Centre at Royal Melbourne Hospital (Melbourne, Australia) and is part of the MSBase team. MSBase is a large global collaboration that involves neurologists, researchers and clinicians from countries ...
Read more : AAN Conference Interview - Personalised medicine in MS | Views : 286 | Replies : 0


 

Login  •  Register


Statistics

Total posts 232507 • Total topics 24864 • Total members 16019


Contact us | Terms of Service